On July 25, 2025, Niagen Bioscience, Inc.'s subsidiary, ChromaDex, entered into a Supply Agreement with W. R. Grace & Co. to exclusively supply Nicotinamide-beta-Riboside Chloride until April 30, 2029, with a minimum purchase commitment. The agreement includes plans for a future licensing deal for manufacturing patents, but final terms are not guaranteed.